What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

TNF Signaling via NF-kB: Pathway, Regulation, and Clinical Relevance

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to TNF Signaling via NF-kB

Tumor necrosis factor (TNF) is a pleiotropic cytokine that orchestrates diverse cellular responses ranging from inflammation and immune activation to proliferation and programmed cell death. First identified in 1975 for its ability to induce hemorrhagic necrosis of tumors, TNF is now recognized as a master regulator of the inflammatory response. The signaling cascades triggered by TNF converge on the transcription factor nuclear factor kappa B (NF-kB), which controls the expression of hundreds of genes involved in immunity, inflammation, cell survival, and tissue homeostasis.

TNF and Its Receptors

TNF exists in two biologically active forms: a 26 kDa transmembrane protein (mTNF) and a soluble 17 kDa cytokine (sTNF) released by proteolytic cleavage via the metalloprotease ADAM17 (also called TACE, TNF-alpha-converting enzyme). Both forms signal through two distinct receptors: TNFR1 (TNFRSF1A, p55/p60) and TNFR2 (TNFRSF1B, p75/p80).

TNFR1 is expressed on virtually all nucleated cells and contains a cytoplasmic death domain (DD) that recruits downstream adaptor proteins. TNFR2 is primarily found on immune cells, endothelial cells, and neurons, and lacks a death domain. While TNFR2 can activate NF-kB, it does so less efficiently than TNFR1 and primarily signals through TRAF2 (TNF receptor-associated factor 2) to promote cell survival and proliferation. The majority of TNF's pro-inflammatory and cytotoxic effects are mediated through TNFR1, making it the principal focus of this article.

NF-kB Family and Activation

NF-kB is a family of dimeric transcription factors composed of five related proteins: NF-kB1 (p50, derived from p105), NF-kB2 (p52, derived from p100), RelA (p65), c-Rel, and RelB. These proteins share a conserved N-terminal Rel homology domain (RHD) that mediates DNA binding, dimerization, and nuclear localization. The most abundant and well-studied NF-kB complex is the p50/RelA heterodimer.

In unstimulated cells, NF-kB dimers are sequestered in the cytoplasm by binding to inhibitor of kappa B (IκB) proteins, primarily IκBα, IκBβ, and IκBε. The canonical NF-kB pathway, which is the focus of TNF signaling, involves the inducible degradation of IκBα, allowing NF-kB to translocate to the nucleus and activate target gene transcription. This pathway is distinct from the non-canonical pathway, which processes p100 to p52 and is activated by a different set of stimuli such as LTβR and BAFF-R. For a broader overview of NF-kB signaling mechanisms, see the Nf Kappa B Signaling Pathway.

The TNF Signaling Cascade

The TNF signaling cascade is a precisely ordered sequence of molecular events that begins with ligand-receptor engagement and culminates in NF-kB nuclear translocation and transcriptional activation.

Receptor Trimerization and Complex I Formation

TNF binding to TNFR1 induces receptor trimerization, which brings the cytoplasmic death domains into close proximity. This clustering recruits the adaptor protein TRADD (TNFR1-associated death domain protein) through homotypic death domain interactions. TRADD then serves as a scaffold for the assembly of additional proteins:

RIPK1 (receptor-interacting serine/threonine-protein kinase 1) binds TRADD via death domain interactions.
TRAF2 and TRAF5 associate with TRADD and RIPK1.
cIAP1/2 (cellular inhibitor of apoptosis proteins 1 and 2) are recruited by TRAF2 and ubiquitylate RIPK1.

This membrane-associated complex, termed Complex I, forms within minutes of TNF stimulation. The key event in Complex I is the K63-linked polyubiquitylation of RIPK1 by cIAP1/2 and the linear ubiquitin chain assembly complex (LUBAC), which consists of HOIP, HOIL-1, and SHARPIN. These ubiquitin chains serve as docking platforms for the recruitment of the TAK1 (TGF-β-activated kinase 1) complex and the IKK (IκB kinase) complex.

IKK Complex Activation

The IKK complex is the master upstream activator of canonical NF-kB signaling. It consists of two catalytic subunits, IKKα (IKK1) and IKKβ (IKK2), and a regulatory subunit, NEMO (NF-kB essential modulator, also called IKKγ). NEMO is essential for the activation of the complex by pro-inflammatory stimuli, as it binds to the K63-linked ubiquitin chains on RIPK1.

The TAK1 complex, composed of TAK1 and its binding partners TAB1, TAB2, and TAB3, is also recruited to the ubiquitin-modified RIPK1. TAB2 and TAB3 contain ubiquitin-binding domains that recognize K63-linked chains, positioning TAK1 in proximity to the IKK complex. TAK1 then phosphorylates IKKβ at serine residues 177 and 181 within its activation loop, leading to IKK complex activation.

The activated IKK complex phosphorylates IκBα at serines 32 and 36. This phosphorylation creates a recognition site for the E3 ubiquitin ligase SCF^βTrCP, which attaches K48-linked polyubiquitin chains to IκBα at lysines 21 and 22. K48-linked ubiquitylation is the canonical signal for proteasomal degradation.

IκB Degradation and NF-kB Release

The K48-ubiquitylated IκBα is rapidly degraded by the 26S proteasome, typically within 5–10 minutes of TNF stimulation. This degradation exposes the nuclear localization sequence (NLS) on the p50 subunit of the NF-kB dimer, allowing the p50/RelA complex to translocate into the nucleus.

Once in the nucleus, NF-kB binds to specific DNA sequences called κB sites, which have the consensus sequence 5'-GGGRNNYYCC-3' (where R is purine, Y is pyrimidine, and N is any nucleotide). NF-kB binding recruits coactivators such as CBP/p300, which possess histone acetyltransferase activity and promote chromatin remodeling and transcriptional activation.

NF-kB target genes include pro-inflammatory cytokines (TNF, IL-1β, IL-6), chemokines (IL-8, MCP-1), adhesion molecules (ICAM-1, VCAM-1, E-selectin), inducible enzymes (iNOS, COX-2), and anti-apoptotic proteins (cIAP1/2, Bcl-xL, A20, c-FLIP). The transcriptional response is rapid, with target gene mRNA appearing within 30–60 minutes of stimulation.

Regulation of TNF-Induced NF-kB Signaling

The TNF-NF-kB pathway is subject to multiple layers of negative regulation that prevent excessive or prolonged inflammation. These regulatory mechanisms operate at the level of receptor signaling, IKK activity, and NF-kB transcriptional activity.

A20 and CYLD Deubiquitinases

A20 (TNFAIP3) is a dual-function enzyme that serves as a critical negative feedback regulator of TNF signaling. A20 contains an N-terminal ovarian tumor (OTU) domain with deubiquitinase activity that removes K63-linked ubiquitin chains from RIPK1, and a C-terminal zinc finger domain with E3 ligase activity that adds K48-linked chains, targeting RIPK1 for proteasomal degradation. A20 is itself a transcriptional target of NF-kB, creating a negative feedback loop that limits the duration and magnitude of signaling.

CYLD (cylindromatosis) is another deubiquitinase that removes K63-linked ubiquitin chains from RIPK1, TRAF2, and NEMO. Unlike A20, CYLD is constitutively expressed and acts as a basal brake on the pathway. Loss-of-function mutations in CYLD are associated with cylindromatosis, a condition characterized by benign skin tumors, highlighting its tumor-suppressive role.

IκB Resynthesis

A second negative feedback loop involves the NF-kB-dependent resynthesis of IκBα. The NFKBIA gene, encoding IκBα, contains functional κB sites in its promoter and is rapidly transcribed following NF-kB activation. Newly synthesized IκBα enters the nucleus, removes NF-kB from DNA, and exports the complex back to the cytoplasm, terminating the transcriptional response.

This resynthesis occurs within 30–60 minutes of stimulation and explains the characteristic oscillatory or pulse-like pattern of NF-kB nuclear localization observed in live-cell imaging studies. The kinetics of IκBα resynthesis are critical: if IκBα production is delayed or impaired, NF-kB activity is prolonged, leading to excessive inflammation.

Post-translational Modifications

NF-kB activity is further modulated by post-translational modifications of the RelA subunit. Phosphorylation of RelA at serine 536 by IKKβ or other kinases enhances its transcriptional activity, while phosphorylation at serine 276 by protein kinase A (PKA) promotes interaction with CBP/p300. Acetylation of RelA at lysine 310 by CBP/p300 also enhances transcriptional activity, whereas deacetylation by HDAC3 reduces it.

These modifications allow for stimulus-specific and cell-type-specific regulation of NF-kB target gene expression, providing a mechanism for fine-tuning the inflammatory response without altering the core pathway.

Crosstalk with Other Signaling Pathways

TNF signaling does not operate in isolation. The pathway intersects with multiple other signaling cascades, and the integrated output determines cellular fate.

JNK and p38 MAPK Pathways

TNF also activates the mitogen-activated protein kinase (MAPK) pathways, including JNK (c-Jun N-terminal kinase) and p38 MAPK. These pathways branch from Complex I at the level of TAK1, which phosphorylates and activates MKK4/MKK7 (upstream of JNK) and MKK3/MKK6 (upstream of p38).

JNK phosphorylates c-Jun, a component of the AP-1 transcription factor, which cooperates with NF-kB to regulate inflammatory gene expression. p38 MAPK phosphorylates and stabilizes mRNAs containing AU-rich elements (AREs) in their 3' untranslated regions, many of which encode inflammatory cytokines. This post-transcriptional regulation is essential for robust cytokine production.

The MAPK pathways also influence NF-kB signaling through cross-phosphorylation. For example, p38 MAPK can phosphorylate TTP (tristetraprolin), an ARE-binding protein that promotes mRNA degradation, thereby regulating the stability of NF-kB target gene transcripts.

Apoptosis vs. Survival Decisions

TNF signaling can trigger both pro-survival and pro-death outcomes, and the balance between NF-kB and caspase activation determines the cellular response. TNFR1 contains a death domain, and when Complex I fails to form properly—for example, when cIAP1/2 are depleted or RIPK1 ubiquitylation is impaired—a secondary complex (Complex II) forms in the cytoplasm.

Complex II contains TRADD, RIPK1, FADD (Fas-associated death domain protein), and procaspase-8. Proximity-induced dimerization of procaspase-8 leads to its autoproteolytic activation, initiating the extrinsic apoptotic cascade. NF-kB activation prevents this by inducing the expression of anti-apoptotic proteins such as c-FLIP (which inhibits caspase-8 activation), cIAP1/2, and Bcl-xL.

This dual signaling explains why TNF is cytotoxic to some cells (where NF-kB activation is insufficient) but survival-promoting in others. It also underlies the phenomenon of NF-kB inhibition sensitizing cancer cells to TNF-induced apoptosis, a strategy explored in cancer therapy. The interplay between survival and death pathways is a recurring theme in cell signaling, as also observed in the Notch Signaling Pathway, where context determines proliferative versus differentiation outcomes.

Physiological Roles of TNF-NF-kB Signaling

TNF-NF-kB signaling is essential for normal immune function and tissue homeostasis. Its dysregulation contributes to numerous pathological conditions.

Innate Immunity and Inflammation

TNF is a primary mediator of the innate immune response to infection and tissue injury. Produced mainly by activated macrophages and monocytes, TNF acts on endothelial cells to increase vascular permeability and upregulate adhesion molecules, facilitating leukocyte extravasation into sites of inflammation. It also activates neutrophils and macrophages, enhancing their phagocytic and bactericidal activities.

The NF-kB-dependent induction of pro-inflammatory cytokines (IL-1β, IL-6), chemokines (IL-8, MCP-1), and adhesion molecules (ICAM-1, VCAM-1) creates a positive feedback loop that amplifies the inflammatory response. This amplification is normally controlled by the negative regulators described above, but when these fail, chronic inflammation ensues.

TNF also plays a critical role in the acute-phase response, inducing the liver to produce acute-phase proteins such as C-reactive protein (CRP) and serum amyloid A. These proteins opsonize pathogens and activate complement, contributing to pathogen clearance.

Cell Survival and Proliferation

Beyond inflammation, TNF-NF-kB signaling promotes cell survival and proliferation in various cell types. NF-kB target genes include cyclin D1, which drives G1/S cell cycle progression, and c-Myc, a master regulator of cell growth. In lymphocytes, TNF signaling costimulates proliferation and differentiation, contributing to adaptive immune responses.

In the liver, TNF-NF-kB signaling is essential for hepatocyte survival and regeneration following injury. Mice lacking IKKβ in hepatocytes exhibit massive hepatocyte apoptosis during development and are highly susceptible to TNF-induced liver failure. Similarly, NF-kB activation in intestinal epithelial cells maintains gut barrier integrity and prevents bacterial translocation.

Dysregulation in Disease

Aberrant TNF-NF-kB signaling underlies a wide range of human diseases, from chronic inflammatory conditions to cancer.

Chronic Inflammatory Diseases

Excessive or sustained TNF-NF-kB signaling is a hallmark of chronic inflammatory diseases, including rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, and asthma. In RA, TNF produced by synovial macrophages drives the expression of matrix metalloproteinases (MMPs) and receptor activator of NF-kB ligand (RANKL) in synovial fibroblasts, leading to cartilage destruction and bone erosion.

In IBD, dysregulated TNF signaling in intestinal macrophages and T cells promotes mucosal inflammation, epithelial barrier disruption, and tissue damage. Genome-wide association studies have identified polymorphisms in TNFAIP3 (encoding A20) and NFKB1 that increase susceptibility to IBD, underscoring the importance of negative regulation in preventing disease.

Cancer and NF-kB

NF-kB is constitutively activated in many human cancers, including lymphomas, leukemias, breast, colon, and pancreatic cancers. This constitutive activation can arise from mutations in upstream regulators (e.g., loss of A20 in Hodgkin lymphoma), autocrine TNF production by tumor cells, or chronic inflammation in the tumor microenvironment.

NF-kB promotes tumorigenesis through multiple mechanisms: it induces anti-apoptotic genes (Bcl-xL, cIAP1/2, c-FLIP) that confer resistance to chemotherapy and radiation; it drives proliferation through cyclin D1 and c-Myc; it promotes angiogenesis via VEGF and IL-8; and it facilitates metastasis by inducing MMPs and adhesion molecules. The tumor-promoting role of NF-kB is particularly evident in inflammation-associated cancers, such as colitis-associated colorectal cancer, where NF-kB activation in both tumor cells and immune cells fuels tumor progression.

The parallels between NF-kB and other developmental signaling pathways in cancer are instructive. Like the Wnt Signaling in Cancer pathway, NF-kB activation provides survival and proliferative advantages to cancer cells, and both pathways are attractive therapeutic targets.

Methods to Study TNF-NF-kB Signaling

Studying TNF-NF-kB signaling requires a combination of biochemical, cell biological, and genetic approaches. The following methods are commonly used in research laboratories.

Reporter Assays

NF-kB reporter assays measure transcriptional activity by placing a reporter gene (luciferase, GFP, or β-galactosidase) under the control of a promoter containing NF-kB binding sites. Cells are transfected with the reporter construct, stimulated with TNF, and reporter activity is measured.

For luciferase assays, cells are lysed in a buffer containing 25 mM Tris-phosphate (pH 7.8), 2 mM DTT, 2 mM 1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid, 10% glycerol, and 1% Triton X-100. Luciferase activity is measured after adding luciferin substrate and ATP, with light output quantified using a luminometer. Results are typically normalized to a co-transfected control reporter (e.g., Renilla luciferase) to correct for transfection efficiency.

Western Blotting and Immunofluorescence

Western blotting is used to assess the phosphorylation and degradation of pathway components. Key readouts include:

IκBα degradation: Total IκBα levels decrease within 5–15 minutes of TNF stimulation and recover by 60–90 minutes.
IKKβ phosphorylation: Phosphorylation at S177/S181 indicates IKK activation.
RelA phosphorylation: Phosphorylation at S536 indicates transcriptional activation.
RIPK1 ubiquitylation: High molecular weight smears indicate polyubiquitylation.

For phospho-specific detection, cells are lysed in RIPA buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS) supplemented with protease and phosphatase inhibitors. Samples are separated by SDS-PAGE, transferred to PVDF membranes, and probed with specific antibodies.

Immunofluorescence allows visualization of NF-kB subcellular localization. Cells are fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton X-100, and stained with anti-RelA antibodies. In unstimulated cells, RelA is cytoplasmic; after TNF stimulation, it accumulates in the nucleus within 15–30 minutes.

Genetic Knockouts and siRNA

Genetic approaches are essential for establishing causality. siRNA or shRNA-mediated knockdown of pathway components (e.g., RIPK1, IKKβ, NEMO) can be performed in cell lines, while CRISPR-Cas9 gene editing enables complete knockout. Mouse knockout models have been generated for most pathway components:

TNFR1 knockout: Resistant to TNF-induced septic shock and inflammation.
IKKβ knockout: Embryonic lethal due to massive hepatocyte apoptosis.
RelA knockout: Embryonic lethal at E15 due to liver degeneration.
A20 knockout: Spontaneous severe inflammation and cachexia, dying within 3 weeks of birth.

These models have been instrumental in defining the physiological and pathological roles of TNF-NF-kB signaling.

Therapeutic Targeting of TNF-NF-kB

The central role of TNF-NF-kB signaling in disease has made it a major target for therapeutic intervention.

TNF Blockers in Clinics

TNF inhibitors are among the most successful biologic drugs in clinical use. Five TNF blockers are FDA-approved:

Drug	Type	Target	Clinical Use
Infliximab	Chimeric monoclonal antibody	Soluble and transmembrane TNF	RA, IBD, psoriasis, ankylosing spondylitis
Adalimumab	Fully human monoclonal antibody	Soluble and transmembrane TNF	RA, IBD, psoriasis, uveitis
Etanercept	TNFR2-Fc fusion protein	Soluble TNF (not transmembrane)	RA, psoriasis, ankylosing spondylitis
Certolizumab pegol	PEGylated Fab fragment	Soluble and transmembrane TNF	RA, Crohn's disease
Golimumab	Fully human monoclonal antibody	Soluble and transmembrane TNF	RA, ulcerative colitis, ankylosing spondylitis

These agents neutralize TNF, preventing receptor engagement and downstream NF-kB activation. They are highly effective in reducing inflammation and improving clinical outcomes, though they carry risks of increased susceptibility to infections, particularly reactivation of latent tuberculosis.

NF-kB Inhibitors in Development

Direct NF-kB inhibitors have been more challenging to develop due to the pathway's essential role in normal immune function. However, several strategies are being explored:

IKKβ inhibitors: Small molecules such as BMS-345541 and MLN120B inhibit IKKβ kinase activity. These have shown efficacy in preclinical models of inflammation and cancer but have faced toxicity concerns in clinical trials.
Proteasome inhibitors: Bortezomib, approved for multiple myeloma, blocks IκBα degradation by inhibiting the proteasome, thereby reducing NF-kB activity. Its efficacy in myeloma is partly attributed to NF-kB inhibition, as myeloma cells are dependent on NF-kB for survival.
NEMO-binding domain (NBD) peptides: Cell-permeable peptides that disrupt NEMO-IKKβ interaction specifically inhibit canonical NF-kB activation without affecting basal NF-kB activity. These have shown promise in animal models of inflammation.
Deubiquitinase inhibitors: Compounds targeting A20 or CYLD are being explored, though specificity remains a challenge.

The therapeutic window for NF-kB inhibitors is narrow, and the challenge is to achieve sufficient pathway inhibition to suppress disease without compromising host defense.

Common Pitfalls and Practical Considerations

Students and researchers studying TNF-NF-kB signaling frequently encounter several conceptual and experimental pitfalls.

Overlooking Negative Feedback

A common mistake is to assume that NF-kB activation is a simple on-off switch. In reality, the pathway is highly dynamic, with negative feedback loops creating pulses of NF-kB activity. IκBα resynthesis and A20 induction occur within 30–60 minutes of stimulation, meaning that the window for detecting IκBα degradation is narrow. If samples are collected too late, IκBα levels will have recovered, and the degradation will be missed.

Similarly, when interpreting reporter assays, the timing of measurement matters. Luciferase activity peaks at 4–6 hours post-stimulation and declines thereafter. Measuring at a single time point can miss the dynamics of the response.

Misinterpreting NF-kB Localization

NF-kB localization is often used as a proxy for activation, but this can be misleading. Nuclear localization does not always correlate with transcriptional activity. RelA can be nuclear but transcriptionally inactive if it lacks appropriate post-translational modifications or coactivator recruitment. Conversely, a small pool of NF-kB may be constitutively nuclear in some cell types.

Immunofluorescence experiments should be complemented with functional assays (reporter assays, target gene expression) to confirm transcriptional activity. Additionally, fixation and permeabilization conditions can affect the apparent localization; methanol fixation can extract cytoplasmic proteins and create artifactual nuclear staining.

Ignoring Cell-Type Specificity

TNF responses vary dramatically between cell types. Fibroblasts, endothelial cells, macrophages, and epithelial cells express different levels of TNFR1, TNFR2, and downstream regulators, leading to quantitative and qualitative differences in NF-kB activation. For example, endothelial cells show rapid and robust NF-kB activation, while some epithelial cell lines are relatively resistant.

Results obtained in one cell line should not be extrapolated to others without validation. Primary cells often respond differently from immortalized cell lines, and 2D culture conditions may not recapitulate in vivo behavior. When studying TNF signaling, it is essential to validate key findings in multiple cell types or in vivo models.

Frequently Asked Questions

What is the role of NF-kB in TNF signaling?

NF-kB is the principal transcription factor activated by TNF. It translocates to the nucleus following TNF stimulation and drives the expression of hundreds of genes involved in inflammation, cell survival, proliferation, and immune regulation. NF-kB activation is the primary mechanism by which TNF exerts its pro-inflammatory and pro-survival effects.

How does TNF activate NF-kB?

TNF binds to TNFR1, inducing receptor trimerization and recruitment of TRADD, RIPK1, TRAF2/5, and cIAP1/2. RIPK1 is ubiquitylated with K63-linked chains, recruiting the TAK1 and IKK complexes. IKKβ phosphorylates IκBα, marking it for K48-linked ubiquitylation and proteasomal degradation. This releases NF-kB dimers, which translocate to the nucleus and activate target gene transcription.

What is the difference between canonical and non-canonical NF-kB signaling?

The canonical pathway, activated by TNF, IL-1, and TLR ligands, involves IKKβ-dependent IκBα degradation and nuclear translocation of p50/RelA dimers. The non-canonical pathway, activated by LTβR, BAFF-R, and CD40, involves NIK-dependent processing of p100 to p52 and nuclear translocation of p52/RelB dimers. The non-canonical pathway is slower and regulates a distinct set of genes involved in lymphoid organ development and B-cell function.

Why is TNF signaling important in inflammation?

TNF is a master pro-inflammatory cytokine. TNF-induced NF-kB activation leads to the expression of cytokines, chemokines, adhesion molecules, and inflammatory enzymes that recruit immune cells, increase vascular permeability, and amplify the inflammatory response. TNF also activates the acute-phase response and promotes fever. While essential for host defense, excessive TNF signaling causes chronic inflammation and tissue damage.

What are the negative regulators of TNF-NF-kB signaling?

Key negative regulators include A20 (a deubiquitinase that removes K63 chains from RIPK1), CYLD (another deubiquitinase), IκBα (which is resynthesized and sequesters NF-kB in the cytoplasm), and various phosphatases that inactivate IKK. These regulators create negative feedback loops that limit the duration and magnitude of NF-kB activation.

How is TNF-NF-kB signaling studied experimentally?

Common approaches include NF-kB reporter assays (luciferase or GFP), Western blotting for IκBα degradation and IKK phosphorylation, immunofluorescence for RelA nuclear translocation, electrophoretic mobility shift assays (EMSA) for DNA binding, and genetic manipulation (siRNA, CRISPR, knockout mice) to test the role of specific components.

What diseases are associated with dysregulated TNF-NF-kB signaling?

Chronic inflammatory diseases (rheumatoid arthritis, IBD, psoriasis, asthma), cancer (lymphomas, breast, colon, pancreatic), autoimmune disorders (multiple sclerosis, lupus), and metabolic diseases (obesity-associated insulin resistance, atherosclerosis) are all associated with dysregulated TNF-NF-kB signaling.

What are TNF inhibitors and how do they work?

TNF inhibitors are biologic drugs that neutralize TNF activity. They include monoclonal antibodies (infliximab, adalimumab, golimumab, certolizumab) and a soluble receptor fusion protein (etanercept). These agents bind to soluble and/or transmembrane TNF, preventing it from engaging TNFR1 and TNFR2, thereby blocking downstream NF-kB activation and inflammation.

Key Takeaways

TNF signals primarily through TNFR1, recruiting TRADD, RIPK1, TRAF2, and cIAP1/2 to form Complex I, which activates the IKK complex.
IKKβ phosphorylates IκBα, triggering its K48-linked ubiquitylation and proteasomal degradation, releasing NF-kB (p50/RelA) for nuclear translocation.
NF-kB drives expression of pro-inflammatory cytokines, chemokines, adhesion molecules, and anti-apoptotic proteins, making it a central regulator of inflammation and cell survival.
Negative feedback regulators (A20, CYLD, IκBα resynthesis) are essential for terminating NF-kB signaling; their failure causes chronic inflammation.
TNF signaling integrates with MAPK pathways (JNK, p38) and apoptotic cascades, with the balance between NF-kB survival signals and caspase activation determining cell fate.
Dysregulated TNF-NF-kB signaling underlies chronic inflammatory diseases and many cancers, making it a major therapeutic target.
TNF inhibitors are highly effective clinically, while direct NF-kB inhibitors remain in development due to challenges in achieving specificity without compromising host defense.